Language:

Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review

Viruses, 2020-05, Vol.12 (5), p.527 [Peer Reviewed Journal]

COPYRIGHT 2020 MDPI AG ;2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 1999-4915 ;EISSN: 1999-4915 ;DOI: 10.3390/v12050527 ;PMID: 32403242

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review
Author: Aboughdir, Maryam ; Kirwin, Thomas ; Abdul Khader, Ashiq ; Wang, Brian
Subjects: Analysis ; Betacoronavirus ; Biological markers ; Biomarkers ; Biomarkers - blood ; Cardiac patients ; cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - complications ; China ; Comorbidity ; Coronaviridae ; coronavirus ; Coronavirus Infections - blood ; Coronavirus Infections - complications ; Coronaviruses ; COVID-19 ; Health aspects ; Humans ; Infectivity ; Intensive care units ; Morbidity ; Mortality ; Pandemics ; Pneumonia, Viral - blood ; Pneumonia, Viral - complications ; Prognosis ; Review ; Risk factors ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; United Kingdom ; Viral research
Is Part Of: Viruses, 2020-05, Vol.12 (5), p.527
Description: In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes.
Publisher: Switzerland: MDPI AG
Language: English
Identifier: ISSN: 1999-4915
EISSN: 1999-4915
DOI: 10.3390/v12050527
PMID: 32403242
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
ProQuest Databases
PubMed Central
DOAJ: Directory of Open Access Journals
Coronavirus Research Database
ROAD: Directory of Open Access Scholarly Resources

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review

Searching Remote Databases, Please Wait